

MAY 18 2009

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

The Nath Law Group 112 South West Street Alexandria, VA 22314 In Re: Patent Term Extension
Application for
U.S. Patent No. 5,482,934

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 5,482,934 for a period of 1,749 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website: http://www.fda.gov/opacom/morechoices/fdaforms/default.html (http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf).

Inquiries regarding this communication should be directed to Raul Tamayo by telephone at (571) 272-7728, or by e-mail at raul.tamayo@uspto.gov.

Mary C. Till

Legal Advisor

Office of Patent Legal Administration Office of the Deputy Commissioner for Patent Examination Policy

cc: Office of Regulatory Policy

Food and Drug Administration

10903 New Hampshire Ave., Bldg. 51, Rm. 6222

Silver Spring, MD 20993-0002

Attention: Beverly Friedman

RE: OMNARIS® (ciclesonide)

FDA Docket No.: FDA-2007-E-0398

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

(68) PATENT NO. : 5,482,934

(45) ISSUED : January 9, 1996

(75) INVENTOR : Jose Calatayud et al.

(73) PATENT OWNER : NYCOMED GmbH

(95) PRODUCT : OMNARIS® (ciclesonide)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,482,934 based upon the regulatory review of the product OMNARIS® (ciclesonide) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 1,749 days

from January 9, 2013, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 13th day of May 2009.

JOHN L'DOLL

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office